CARDINAL HEALTH 414 is a specialty pharmaceutical company focused on Oncology, Neurology. Key products include LYMPHOSEEK KIT.
CARDINAL HEALTH 414's Key Drugs
CARDINAL HEALTH 414's core commercial portfolio centers on LYMPHOSEEK KIT, spanning Oncology and Neurology — its most strategically important drugs approved in the last 15 years.
CARDINAL HEALTH 414's Recent FDA Approvals
New NDA/BLA approvals for CARDINAL HEALTH 414 over the last two years — novel drugs only, excluding generics and label supplements.
CARDINAL HEALTH 414's Therapeutic Areas
CARDINAL HEALTH 414's approved drugs and pipeline span 2 therapeutic areas, led by Oncology and Neurology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
CARDINAL HEALTH 414's Top Competitors
CARDINAL HEALTH 414's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
CARDINAL HEALTH 414 Pipeline Snapshot
CARDINAL HEALTH 414 has 3 active clinical programs from ClinicalTrials.gov — 0 Phase 3, 3 Phase 2 and 0 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • LYMPHOSEEK KIT leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 1981-02-17
- Latest
- 2025-05-22
- Applications
- 5